Calidi Biotherapeutics Inc (CLDI)

$1.34 0.00 (N/A)
Market Cap 1.62M
Revenue (ttm) 0.00
Net Income (ttm) -19.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.19
Volume 58,900
Avg Vol 346,236
Day's Range N/A - N/A
Shares Out 1.21M
Stochastic %K 20%
Beta 1.33
Analysts Strong Buy
Price Target $10.00

Company Profile

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 9600
Fax: 858 794 9605
Address:
4475 Executive Drive, Suite 200, San Diego, United States
race2zero
race2zero Aug. 21 at 12:16 PM
$CLDI 500 volume😂😂😂. They will give up and have to start dilution soon. Ingredients of an epic short: low volume, dilution, incompetent management, zero percent chance of actually getting an approved product before they run out of money…
1 · Reply
race2zero
race2zero Aug. 21 at 11:48 AM
$CLDI don’t let these propaganda posts fool you, this company only wants to try and raise the price to dilute to pay their salaries…@CalidiOfficial
0 · Reply
TheOne_24
TheOne_24 Aug. 21 at 6:07 AM
$CYCU $LIMN $CLDI $VTAK $VBIO
0 · Reply
MoneyMacG
MoneyMacG Aug. 20 at 6:36 PM
$EJH $INDP $CLDI $BDRX $JBDI checking
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 19 at 7:33 PM
Mathematical Study Offers Possible Fix to Melanoma Therapy Mystery $CLDI #TinyGems #Melanoma https://ibn.fm/jnQaQ
0 · Reply
race2zero
race2zero Aug. 19 at 1:16 PM
$CLDI come on Andrew Jackson, let’s start that dilution!
0 · Reply
race2zero
race2zero Aug. 19 at 1:13 PM
$CLDI heading under $1 before they even start the dilution 🤣🤣🤣
0 · Reply
race2zero
race2zero Aug. 18 at 6:39 PM
$CLDI well this explains today’s drop🤣🤣🤣🤣
0 · Reply
race2zero
race2zero Aug. 18 at 6:16 PM
$CLDI already bought the land overlooking the Ocean in Ensenada, Mexico. Planning the build now, as soon as dilution hits, this short will pay for the entire project.
0 · Reply
race2zero
race2zero Aug. 18 at 6:05 PM
$CLDI 🤣🤣🤣
1 · Reply
Latest News on CLDI
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 13, 2026, 4:30 PM EDT - 10 days ago

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

Jul 27, 2026, 8:00 AM EDT - 27 days ago

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Jul 21, 2026, 8:00 AM EDT - 4 weeks ago

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

Jul 20, 2026, 4:30 PM EDT - 4 weeks ago

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Jul 8, 2026, 4:05 PM EDT - 6 weeks ago

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit

Jun 24, 2026, 8:00 AM EDT - 2 months ago

Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Jun 23, 2026, 8:00 AM EDT - 2 months ago

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Calidi receives pre-IND regulatory feedback from FDA for CLD-401

2026-06-16T12:39:20.000Z - 2 months ago

Calidi receives pre-IND regulatory feedback from FDA for CLD-401

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

Jun 16, 2026, 8:00 AM EDT - 2 months ago

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026

Calidi announces online abstract acceptances at 2026 ASCO Meeting

2026-05-26T15:37:20.000Z - 3 months ago

Calidi announces online abstract acceptances at 2026 ASCO Meeting

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting

May 26, 2026, 8:00 AM EDT - 3 months ago

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting

Calidi provides required NYSE American disclosure

2026-05-22T22:05:57.000Z - 3 months ago

Calidi provides required NYSE American disclosure

Calidi Biotherapeutics Provides Required NYSE American Disclosure

May 22, 2026, 6:00 PM EDT - 3 months ago

Calidi Biotherapeutics Provides Required NYSE American Disclosure

Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights

May 14, 2026, 4:10 PM EDT - 3 months ago

Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston

May 13, 2026, 8:00 AM EDT - 3 months ago

Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston

Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI

Calidi presents new data on CLD-401 at AACR

2026-04-21T13:29:48.000Z - 4 months ago

Calidi presents new data on CLD-401 at AACR

Calidi presents new data on in situ t-cell engagers at AACR

2026-04-20T12:54:38.000Z - 4 months ago

Calidi presents new data on in situ t-cell engagers at AACR

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

Mar 27, 2026, 4:25 PM EDT - 5 months ago

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

Calidi presents manufacturing process for CDI-401 at BioProcessing Summit

2026-03-12T12:17:48.000Z - 5 months ago

Calidi presents manufacturing process for CDI-401 at BioProcessing Summit

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

Mar 9, 2026, 8:50 PM EDT - 5 months ago

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

Calidi prices 10.5M units at 50c in underwritten public offering

2026-03-06T13:35:48.000Z - 6 months ago

Calidi prices 10.5M units at 50c in underwritten public offering

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering

Mar 6, 2026, 8:30 AM EST - 6 months ago

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering

Calidi announces offering of units, no amount given

2026-03-05T23:00:46.000Z - 6 months ago

Calidi announces offering of units, no amount given

Calidi Biotherapeutics Announces Proposed Public Offering

Mar 5, 2026, 5:57 PM EST - 6 months ago

Calidi Biotherapeutics Announces Proposed Public Offering

Calidi presents data on novel approach to use of BiTEs

2026-02-20T13:11:19.000Z - 6 months ago

Calidi presents data on novel approach to use of BiTEs

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

Feb 20, 2026, 8:00 AM EST - 6 months ago

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

Calidi to present on approach to bispecific T-cell engagers using RedTail

2026-02-12T13:10:13.000Z - 6 months ago

Calidi to present on approach to bispecific T-cell engagers using RedTail

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

Feb 12, 2026, 8:00 AM EST - 6 months ago

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

Calidi announces 2026 milestones

2026-01-28T13:13:01.000Z - 7 months ago

Calidi announces 2026 milestones

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

Nov 17, 2025, 8:00 AM EST - 9 months ago

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights

Nov 13, 2025, 4:15 PM EST - 10 months ago

Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights

Calidi presents new data on CLD-401 at 2025 SITC annual meeting

2025-11-10T13:20:35.000Z - 10 months ago

Calidi presents new data on CLD-401 at 2025 SITC annual meeting

Calidi announces new data to be presented on CLD-401 at 2025 SITC meeting

2025-10-30T12:15:32.000Z - 10 months ago

Calidi announces new data to be presented on CLD-401 at 2025 SITC meeting

Calidi announces formation of its Scientific Advisory Board

2025-10-22T12:11:42.000Z - 10 months ago

Calidi announces formation of its Scientific Advisory Board

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

Aug 21, 2025, 6:33 PM EDT - 1 year ago

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

Calidi prices 1.47M units at $2.00 in underwritten public offering

2025-08-20T13:20:27.000Z - 1 year ago

Calidi prices 1.47M units at $2.00 in underwritten public offering

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

Aug 20, 2025, 9:15 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

Aug 8, 2025, 4:15 PM EDT - 1 year ago

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Inc trading resumes

2025-08-05T13:46:30.000Z - 1 year ago

Calidi Biotherapeutics Inc trading resumes

Calidi Biotherapeutics Inc trading halted, volatility trading pause

2025-08-05T13:43:07.000Z - 1 year ago

Calidi Biotherapeutics Inc trading halted, volatility trading pause

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Jul 25, 2025, 4:45 PM EDT - 1 year ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment

Jul 10, 2025, 8:30 AM EDT - 1 year ago

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

Jul 9, 2025, 2:01 PM EDT - 1 year ago

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

Calidi Biotherapeutics Announces Shareholder Letter from CEO

Jun 27, 2025, 8:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Shareholder Letter from CEO

Global X Offers Precise U.S. Equity Exposure with Launch of Domestic Focused Funds

Apr 16, 2025, 9:30 AM EDT - 1 year ago

Global X Offers Precise U.S. Equity Exposure with Launch of Domestic Focused Funds

EGLE

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Mar 28, 2025, 9:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 28, 2025, 9:00 AM EST - 1 year ago

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

Feb 24, 2025, 8:00 AM EST - 1 year ago

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5

Jan 29, 2025, 8:00 AM EST - 1 year ago

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

Jan 28, 2025, 8:00 AM EST - 1 year ago

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Jan 10, 2025, 4:30 PM EST - 1 year ago

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

Jan 10, 2025, 8:30 AM EST - 1 year ago

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Nov 15, 2024, 4:05 PM EST - 1 year ago

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

Nov 14, 2024, 8:30 AM EST - 1 year ago

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Nov 12, 2024, 5:29 PM EST - 1 year ago

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Oct 25, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NXL

race2zero
race2zero Aug. 21 at 12:16 PM
$CLDI 500 volume😂😂😂. They will give up and have to start dilution soon. Ingredients of an epic short: low volume, dilution, incompetent management, zero percent chance of actually getting an approved product before they run out of money…
1 · Reply
race2zero
race2zero Aug. 21 at 11:48 AM
$CLDI don’t let these propaganda posts fool you, this company only wants to try and raise the price to dilute to pay their salaries…@CalidiOfficial
0 · Reply
TheOne_24
TheOne_24 Aug. 21 at 6:07 AM
$CYCU $LIMN $CLDI $VTAK $VBIO
0 · Reply
MoneyMacG
MoneyMacG Aug. 20 at 6:36 PM
$EJH $INDP $CLDI $BDRX $JBDI checking
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 19 at 7:33 PM
Mathematical Study Offers Possible Fix to Melanoma Therapy Mystery $CLDI #TinyGems #Melanoma https://ibn.fm/jnQaQ
0 · Reply
race2zero
race2zero Aug. 19 at 1:16 PM
$CLDI come on Andrew Jackson, let’s start that dilution!
0 · Reply
race2zero
race2zero Aug. 19 at 1:13 PM
$CLDI heading under $1 before they even start the dilution 🤣🤣🤣
0 · Reply
race2zero
race2zero Aug. 18 at 6:39 PM
$CLDI well this explains today’s drop🤣🤣🤣🤣
0 · Reply
race2zero
race2zero Aug. 18 at 6:16 PM
$CLDI already bought the land overlooking the Ocean in Ensenada, Mexico. Planning the build now, as soon as dilution hits, this short will pay for the entire project.
0 · Reply
race2zero
race2zero Aug. 18 at 6:05 PM
$CLDI 🤣🤣🤣
1 · Reply
race2zero
race2zero Aug. 18 at 12:18 PM
$CLDI might actually be under $1 before they start dilution🤣. Sometimes I forget how big of idiots Eric Poma and Andrew Jackson are🤣🤣
0 · Reply
MoneyMacG
MoneyMacG Aug. 17 at 8:42 PM
$LGCL $CLIK $CCHH $PETZ $CLDI understand
0 · Reply
race2zero
race2zero Aug. 17 at 8:30 PM
$CLDI 🤣🤣🤣🤣🤣🤣🤣 bruh, this is the biggest bio scam on the market
1 · Reply
Usually_Im_Right
Usually_Im_Right Aug. 17 at 5:45 PM
$CLDI big move low volume… lookjng for big reversal
0 · Reply
race2zero
race2zero Aug. 17 at 4:16 PM
$CLDI @CalidiOfficial it’s over guys…:
0 · Reply
race2zero
race2zero Aug. 17 at 12:44 PM
$CLDI dilution should be announced this week, expect at least a 50% immediate drop followed by a steady slide back down to .20 land
1 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 14 at 7:04 PM
Little-Known Immune Cells Bolster Anticancer Fight, Study Finds $CLDI https://ibn.fm/4DHE2 #biomed #stocks
0 · Reply
race2zero
race2zero Aug. 14 at 6:35 PM
$CLDI
0 · Reply
CalidiOfficial
CalidiOfficial Aug. 14 at 1:52 PM
$CLDI reported Q2 2026 results, including positive FDA pre-IND feedback for CLD-401 and new CLD-501 data presented at ‌ASCO. $CLDI anticipates CLD-401 entering the clinic in Q1 2027 while advancing its RedTail platform. 🔗: https://bit.ly/4qqfL47
0 · Reply
race2zero
race2zero Aug. 14 at 1:04 PM
$CLDI classic bio tech scam
0 · Reply
race2zero
race2zero Aug. 14 at 1:03 PM
$CLDI Friday seems like good day to start the dilution….come on Poma and Jackson, let’s do this!
0 · Reply